欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01477 欧康维视生物-B

未开盘 05-26 16:08:22

6.060

-0.180

-2.88%

最高6.250	最低5.900	成交量103.45万
今开6.250	昨收6.240	日振幅5.61%
总市值49.39亿	流通市值49.39亿	总股本8.15亿
成交额626.20万	换手率0.13%	流通股本8.15亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01477","market":"HK","secType":"STK","nameCN":"欧康维视生物-B","latestPrice":6.06,"timestamp":1779782902005,"preClose":6.24,"halted":0,"volume":1034513,"delay":0,"changeRate":-0.02884615384615394,"floatShares":815000000,"shares":815000000,"eps":-0.2309512801021888,"marketStatus":"未开盘","change":-0.18,"latestTime":"05-26 16:08:22","open":6.25,"high":6.25,"low":5.9,"amount":6262009,"amplitude":0.05609,"askPrice":6.1,"askSize":500,"bidPrice":6.06,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-0.2317977165437633,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779845400000},"marketStatusCode":0,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":6.24,"openAndCloseTimeList":[[1779759000000,1779768000000],[1779771600000,1779782400000]],"volumeRatio":0.90898,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01477","defaultTab":"news","newsList":[{"id":"2638973562","title":"新股消息 | 明宇制药港股IPO招股书失效","url":"https://stock-news.laohu8.com/highlight/detail?id=2638973562","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638973562?lang=zh_cn&edition=full","pubTime":"2026-05-26 10:54","pubTimestamp":1779764061,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，明宇制药有限公司(简称：明宇制药)于2025年11月24日所递交的港股招股书满6个月，于2026年5月24日失效，递表时Morgan Stanley、BofA Securities、CITIC Securities为其联席保荐人。招股书显示，明宇制药于2018年成立，是一家生物技术创新企业。公司具有双重增长引擎：基于专有抗体偶联药物(ADC)平台及一款新型PD-1/VEGF双特异性抗体(bsAb)搭建的稳健的临床阶段肿瘤产品组合，以及向商业化推进的已处于临床后期的自身的免疫资产。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445842.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1191","SPCX","BK4585","VXUS","BK4588","IPOS","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638534935","title":"格隆汇个股放量排行榜 | 5月25日","url":"https://stock-news.laohu8.com/highlight/detail?id=2638534935","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638534935?lang=zh_cn&edition=full","pubTime":"2026-05-25 17:30","pubTimestamp":1779701404,"startTime":"0","endTime":"0","summary":"股票名称成交额（万）量比持续放量天数天利控股集团26177.222.493百富环球2703.382.425中联发展控股1067.482.361优必选217973.061.981华润医疗1719.231.911滔搏3529.591.832胜宏科技350159.461.791数码通电讯961.431.781九龙仓集团17387.851.641蔚来-SW46990.051.551高鑫零售1589.461.521科伦博泰生物60133.001.496九福来102.461.451中集集团7903.471.441北大青鸟环宇360.511.371PACIFIC LEGEND740.851.361中海油田服务9347.601.361MOS HOUSE695.301.331百果园集团641.011.291中芯国际1651388.781.282量化派3423.981.231佰泽医疗5107.781.191时代天使8886.501.192五一视界215348.591.182稀美资源-五百6200.381.1710电讯盈科6323.451.171美格智能7545.751.171深圳高速公路股份1185.201.172森松国际19247.321.143兖矿能源47039.851.111大象未来集团855.821.091通通AI社交2016.021.061兆易创新243","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/05/25173057187788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01919","02259","02155","00117","09866","06990","02050","02172","00177","06110","00004","00384","02598","00165","00107","02685","03888","06613","01592","01473","02609","06681","02714","09880","02291","00081","01672","00981","00008","02565","06699","09993","00909","01211","02506","00087","02587","09626","01477","01516","06603","02418","09869","09926","08547","00152","02142","06955","00199","03986"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2638753551","title":"国金证券：首次覆盖英硅智能(03696)给予“买入”评级 AI制药首个验证里程碑或在眼前","url":"https://stock-news.laohu8.com/highlight/detail?id=2638753551","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638753551?lang=zh_cn&edition=full","pubTime":"2026-05-25 15:05","pubTimestamp":1779692742,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国金证券发布研报称，英硅智能于2025年12月30日在港交所上市，首发价格24.05港元，IPO募资总额约23.5亿港元；其中，约48%/15%/12%/20%将分别用于核心管线临床推进、Pharma.AI平台、自动化实验室以及早研及其他管线开发。首次覆盖，给予“买入”评级。国金证券主要观点如下：验证，全球领先Pharma.AI平台产出PCC30项，FIC）TNIK即将3期。①AI制药行业，进入临床验证期，胜负标准从模型转向结果兑现。AI制药已从模型能力竞争走向数据闭环能力分层。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445552.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ARTY","AGIX","AIPO","03696","CHAT","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637803207","title":"港股异动 | 歌礼制药-B(01672)早盘涨超5% GIC持股比例升至7% ASC30美国II期研究已完成入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2637803207","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637803207?lang=zh_cn&edition=full","pubTime":"2026-05-21 10:57","pubTimestamp":1779332279,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，歌礼制药-B早盘涨超5%，截至发稿，涨4.04%，报15.45港元，成交额1634.76万港元。增持后，GIC持股数量增至7480.8万股，持股比例升至7%。值得注意的是，ASC30用于治疗2型糖尿病的13周美国II期研究已完成入组，预计将于2026年第三季度获得该项治疗2型糖尿病的II期研究的顶线数据。在业内看来，ASC30减重数据优越，安全性良好，且分子专利已获美国授权，BD潜力较大。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444336.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GIC","VXUS","01672","BK1574","BK4585","BK4104","BK1515","01477","BK4588","BK1161","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637870211","title":"已有10%美国人服用，GLP-1正在重塑制药、食品、饮料和餐饮行业","url":"https://stock-news.laohu8.com/highlight/detail?id=2637870211","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637870211?lang=zh_cn&edition=full","pubTime":"2026-05-21 09:47","pubTimestamp":1779328039,"startTime":"0","endTime":"0","summary":"德银调查显示，已有10%的美国人服用过GLP-1类减重药物（如Ozempic、Mounjaro），预计到2030年这一比例将超过20%。更关键的是，服药者在餐厅就餐、点外卖、饮酒等消费行为上大幅下滑，且停药后习惯并未完全恢复，显示出结构性需求转移。","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"6e7a4338b1034ad785d5025385d8625c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3772776","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","BK4144","BK1574","BK4590","BK1191","159151","GLP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636082554","title":"中恒集团（600252）披露梧州制药（香港）公司完成注销公告，5月20日股价下跌2.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636082554","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636082554?lang=zh_cn&edition=full","pubTime":"2026-05-20 22:36","pubTimestamp":1779287777,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘，中恒集团报收于2.25元，较前一交易日下跌2.17%，最新总市值为71.64亿元。近日，广西梧州中恒集团股份有限公司发布《关于中恒集团梧州制药（香港）有限公司完成注销的公告》。公告显示，2025年6月13日，中恒集团召开第十届董事会第二十九次会议，审议通过注销中恒集团梧州制药（香港）有限公司的议案。公司近日收到香港特别行政区公司注册处通知，梧州制药（香港）公司已完成核准解散。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000043481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","600252","BK0012","BK0015","BK0077","01477","BK1574","BK0028","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636291840","title":"制药巨头集体拥抱AI智能体：百时美施贵宝(BMY.US)向3万员工推广Claude","url":"https://stock-news.laohu8.com/highlight/detail?id=2636291840","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636291840?lang=zh_cn&edition=full","pubTime":"2026-05-20 21:05","pubTimestamp":1779282310,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百时美施贵宝正在向其3万多名员工推广Anthropic的旗舰级Claude AI平台，以此扩大人工智能和AI智能体在研究、临床开发及企业运营中的应用。此外，百时美施贵宝表示，它正在使用Anthropic的编程工具Claude Code来加速其软件和AI的开发。该公司还表示，目前正在评估将Claude AI智能体应用于研究、药物开发以及商业和医学事务等领域。Anthropic的竞争对手OpenAI也已与该行业的关键领头羊达成了合作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444152.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0306807586.USD","LU1032466523.USD","IE00BJJMRZ35.SGD","BK4585","LU2125154935.USD","LU0237698245.USD","LU2360032135.SGD","BMY","LU0321505868.SGD","LU1323610961.USD","LU1670711123.USD","LU0321505439.SGD","01477","BK1574","IE0009355771.USD","LU2125154778.USD","IE00B2B36J28.USD","LU0061475181.USD","LU1983299246.USD","LU0432979614.USD","LU0868494617.USD","LU1093756168.USD","BK4534","LU1670710661.SGD","LU0096364046.USD","LU1074936037.SGD","LU1430594728.SGD","LU1868836591.USD","LU1093756325.SGD","LU1868836757.USD","LU2133065610.SGD","159819","BK4588","LU1261432733.SGD","LU1868836914.USD","IE0002141913.USD","LU0225771236.USD","BK4532","IE00BJT1NW94.SGD","LU2242652126.USD","BK1191","LU0114720955.EUR","LU0225284248.USD","LU0985481810.HKD","LU1868837300.USD","LU0267386448.USD","LU1670710588.SGD","IE00BFTCPJ56.SGD","LU2242646821.SGD","IE00BFXG1179.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636855646","title":"全球制药品牌价值50强公布，中国10个品牌上榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2636855646","media":"新浪医药","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636855646?lang=zh_cn&edition=full","pubTime":"2026-05-19 19:30","pubTimestamp":1779190200,"startTime":"0","endTime":"0","summary":"英国品牌评估机构“品牌金融”发布2026“全球医疗保健品牌”价值榜。在“全球制药品牌价值50强”榜单上，强生、礼来、罗氏名列前三位。其中，中国有10个品牌上榜，包括：国药集团 、广药集团 、上海医药 、云南白药 、华东医药 、华润三九 、北京同仁堂 、石药集团 、复星医药  以及片仔癀 。品牌价值被理解为品牌所有者通过在公开市场上许可该品牌所获得的净经济收益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-05-19/doc-inhymumc9908994.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01477","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636077172","title":"再生元制药跌超10%，创年内新低","url":"https://stock-news.laohu8.com/highlight/detail?id=2636077172","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636077172?lang=zh_cn&edition=full","pubTime":"2026-05-18 23:35","pubTimestamp":1779118552,"startTime":"0","endTime":"0","summary":"再生元制药跌超10%，创年内新低","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605183740881112.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605183740881112.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","01477","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636907786","title":"美股异动 | 黑色素瘤药物三期试验未达主要终点 再生元制药(RENG.US)早盘大跌超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636907786","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636907786?lang=zh_cn&edition=full","pubTime":"2026-05-18 23:25","pubTimestamp":1779117917,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周一，再生元制药(RENG.US)早盘大跌超10%，创年内新低，报623.67美元。消息面上，再生元制药公司近日公布了一项三期临床试验的初步结果，其重磅在研药物fianlimab联合Libtayo作为一线疗法，用于治疗无法切除的局部晚期或转移性黑色素瘤时，未能达到主要终点。该试验纳入了1546名患者，是一项随机、双盲研究。结果显示，高剂量联合治疗组的中位无进展生存期为11.5个月，而单独使用默沙东Keytruda的对照组为6.4个月。尽管中位无进展生存期有5.1个月的数值改善，但风险比为0.845，p值为0.0627，未能跨越统计学显著性阈值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443176.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"美股异动 | 黑色素瘤药物三期试验未达主要终点 再生元制药(RENG.US)早盘大跌超10%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","01477","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636026825","title":"再生元制药(REGN)盘前大跌11% 核心药物Ⅲ期试验未达预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2636026825","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636026825?lang=zh_cn&edition=full","pubTime":"2026-05-18 16:53","pubTimestamp":1779094391,"startTime":"0","endTime":"0","summary":"金吾财讯 | 再生元制药（REGN）盘前股价大幅下挫，下跌11.2%，报 619.97 美元。消息面上，。5 月 15 日，再生元制药宣布，其核心药物 fianlimab 联合西米普利单抗的 Ⅲ 期试验未达到主要终点。数据显示，高剂量联合治疗组中位无进展生存期为 11.5 个月，优于对照组的 6.4 个月，但试验 P 值为 0.0627，未达到统计学显著性要求，意味着疗效优势或为偶然结果。此次试验失利直接影响市场对该公司肿瘤领域竞争力的信心。尽管再生元制药将希望寄托于另一项与百时美施贵宝已获批疗法头对头的试验，但此次失败带来的不确定性，仍对其股价造成显著冲击，短期市场信心受挫。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210625/MmNlMmI2NWNjNWI2MzQ2MDk3MTI0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/MmNlMmI2NWNjNWI2MzQ2MDk3MTI0.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"300532","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN","LU1974910355.USD","BK4585","BK1574","LU2023250504.SGD","LU2362540622.SGD","LU0289739699.SGD","BK4588","LU0109394709.USD","LU0823434583.USD","LU2362541513.USD","LU0320765992.SGD","LU0882574055.USD","LU2468319806.SGD","LU0114720955.EUR","LU1917777945.USD","LU2106854487.HKD","BK4139","BK1191","LU0823416689.USD","LU0823434740.USD","LU0889565916.HKD","LU2089984988.USD","LU0053666078.USD","LU2237438978.USD","01477","LU0058720904.USD","LU2362541273.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636302846","title":"港股异动 | 派格生物医药-B(02565)尾盘飙升150% 此前与腾瑞制药达成派达康中国大陆独家商业化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2636302846","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636302846?lang=zh_cn&edition=full","pubTime":"2026-05-18 15:43","pubTimestamp":1779090229,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，派格生物医药-B(02565)尾盘飙升150%，截至发稿，涨106.97%，报23.16港元，成交额7.84亿港元。消息面上，派格生物医药今年3月公布，与腾瑞制药就派达康在中国大陆地区的商业化合作签署战略合作协议。双方在合作协议中确立以实现累计销售规模超过人民币100亿元作为核心商业化目标。根据合作协议，腾瑞制药将向公司支付合计约1.4亿港币的权益金。值得注意的是，5月12日，方舟健客与腾瑞制药举行战略合作签约仪式。本次战略签约后，备受瞩目的创新GLP-1类药物派达康（维培那肽注射液）将于近期在方舟健客互联网医院平台全网首发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442854.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK4585","XBI","BK4581","BK1191","161726","VXUS","01477","BK1161","399441","BK4588","02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635088673","title":"荣昌生物：5月11日召开业绩说明会，《十五五·科创惠民--科创板企业成果转化与民生赋能之2025年度制药行业集体业绩说明》、《\"对话成长\"2025年度暨2026年一季度集体业绩说明会》参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2635088673","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635088673?lang=zh_cn&edition=full","pubTime":"2026-05-15 18:03","pubTimestamp":1778839422,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年5月15日荣昌生物发布公告称公司于2026年5月11日召开业绩说明会，《十五五·科创惠民--科创板企业成果转化与民生赋能之2025年度制药行业集体业绩说明》、《\"对话成长\"2025年度暨2026年一季度集体业绩说明会》参与。泰它西普治疗重症肌无力适应症已于2025年12月成功纳入国家医保目录，目前按医保支付标准执行。公司目前生产经营活动正常，不存在应披露而未披露的重大","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500034801.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09995","BK0239","159982","LU2488822045.USD","688331","LU1064131003.USD","BK1161","BK1574","LU1969619763.USD","LU2148510915.USD","BK1583","LU1064130708.USD","LU2328871848.SGD","BK1191","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635086492","title":"AI制药再添一股：剂泰科技登陆港交所，首日午盘涨超140%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635086492","media":"21世纪经济报道","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635086492?lang=zh_cn&edition=full","pubTime":"2026-05-13 14:33","pubTimestamp":1778653980,"startTime":"0","endTime":"0","summary":"5月13日，剂泰科技（7666.HK）正式在港交所挂牌，成为全球“AI药物递送第一股”，也是港股“AI大分子生物制药第一股”。这家成立仅六年的生物科技公司，以AI驱动的纳米递送技术为突破口，将自身定位为制药界的“SpaceX”，试图在人体30万亿细胞的“内太空”中实现精准导航与治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605133735823337.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605133735823337.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","AGIX","AIPO","BK1574","ARTY","CHAT","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634107952","title":"152亿美元！恒瑞为何能让全球制药巨头疯狂？","url":"https://stock-news.laohu8.com/highlight/detail?id=2634107952","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634107952?lang=zh_cn&edition=full","pubTime":"2026-05-12 22:11","pubTimestamp":1778595060,"startTime":"0","endTime":"0","summary":"5月12日午盘，恒瑞医药突然放出一枚深水炸弹：和全球制药巨头百时美施贵宝（BMS）达成了重磅合作！这笔买卖到底有多大？潜在总交易额高达152亿美元！BMS先支付9.5亿美元首付和近期付款，后面只要药物研发能顺利推下去，恒瑞还能拿到上百亿的里程碑付款，甚至未来的销售分成！这次合作涉及13款早期创新药，主攻肿瘤、血液和免疫疾病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605123734849437.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605123734849437.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","01477","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634212162","title":"欧康维视生物-B(01477)授出购股权及奖励","url":"https://stock-news.laohu8.com/highlight/detail?id=2634212162","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634212162?lang=zh_cn&edition=full","pubTime":"2026-05-12 21:26","pubTimestamp":1778592417,"startTime":"0","endTime":"0","summary":"智通财经APP讯，欧康维视生物-B 发布公告，董事会认为有必要实施激励措施以支持本集团的战略增长目标，并维持人才招聘及留任方面的竞争优势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440893.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634021349","title":"GIC Private Limited增持歌礼制药-B(01672)12.2万股 每股作价16.612港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2634021349","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634021349?lang=zh_cn&edition=full","pubTime":"2026-05-12 19:07","pubTimestamp":1778584055,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，5月7日，GIC Private Limited增持歌礼制药-B(01672)12.2万股，每股作价16.612港元，总金额约为202.67万港元。增持后最新持股数目为7480.8万股，最新持股比例为7.00%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440802.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1191","01672","GIC","EWH","BK1515","BK1574","BK4104","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634290057","title":"剂泰科技港股上市在即：AI制药三小龙会师港股 贝莱德领衔基石 2025年收入增长靠首付款 长期仍具不确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2634290057","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634290057?lang=zh_cn&edition=full","pubTime":"2026-05-12 18:46","pubTimestamp":1778582760,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！本次基石投资者合计认购占比约54.9%。2025年公司实现收入1.05亿元，主要来自管线产品MTS-004的授权首付款，未来商业化收入规模与节奏均存在较大不确定性。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-05-12/doc-inhxrwqf8212666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BLK","LU1064131342.USD","LU1509826696.USD","CHAT","AGIX","BK4588","01477","IE00BVYPNW00.USD","IPOS","LU1291159041.SGD","BK4567","LU2264538146.SGD","LU2430703251.USD","AIPO","IE00BVYPNV92.GBP","IE00B42XCP33.USD","LU1988902786.USD","LU1280957306.USD","LU1481011671.HKD","LU2592432038.USD","LU1201861249.SGD","LU1670628061.USD","IE00B3PB1722.GBP","LU2430703095.HKD","LU0320765489.SGD","IE00BGHQF748.EUR","LU0648001328.SGD","LU1481011911.USD","LU1989771016.USD","LU0742537680.HKD","LU1074936037.SGD","LU0130102774.USD","BK4533","IE00B3QW5Z07.USD","BK4135","LU1599440770.SGD","BK1191","VXUS","ARTY","LU0208291251.USD","LU0640476718.USD","BK4535","LU0157215616.USD","IE00B64PRP62.GBP","LU0772969993.USD","LU0731783394.SGD","BK4581","LU1366333091.USD","LU0731783048.USD","LU2430703178.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634886402","title":"白云山(00874)：天心制药获得注射用头孢呋辛钠0.5g坎地沙坦酯片4mg《药品补充申请批准通知书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2634886402","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634886402?lang=zh_cn&edition=full","pubTime":"2026-05-11 17:33","pubTimestamp":1778492035,"startTime":"0","endTime":"0","summary":"智通财经APP讯，白云山(00874)公布，近日，公司子公司广州白云山天心制药股份有限公司(以下简称“天心制药”)收到国家药品监督管理局签发的注射用头孢呋辛钠0.5g(按C16H16N4O8S计)、坎地沙坦酯片4mg《药品补充申请批准通知书》。天心制药本次获得注射用头孢呋辛钠0.5g(按C16H16N4O8S计)、坎地沙坦酯片4mg《药品补充申请批准通知书》,表明上述药品的杂质药学研究获认可，有利于提升上述产品的质量控制能力和市场竞争力。本次获得上述《药品补充申请批准通知书》，对本公司当期业绩无重大影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440233.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK1574","BK1191","BK0196","600332","BK1521","BK1606","01477","BK0188","BK1515","BK0239","BK0183","BK0028","BK0097","BK0175","BK1197","BK0096","00874","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634408851","title":"港股异动 | 来凯医药-B(02105)午后涨超10% 齐鲁制药推进LAE002上市申请 公司有望获首付款及里程碑款项","url":"https://stock-news.laohu8.com/highlight/detail?id=2634408851","media":"智通财经","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634408851?lang=zh_cn&edition=full","pubTime":"2026-05-11 14:32","pubTimestamp":1778481147,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，来凯医药-B午后涨超10%，截至发稿，涨9.63%，报14.8港元，成交额6089.13万港元。4月30日，齐鲁制药官方宣布，由其独家引进中国区域研发与商业化权益的创新靶向药afuresertib临床研究达到主要终点，齐鲁制药独家引进推进国内上市申请。作为回报，若LAE002在中国获批首个适应症，来凯医药有权获得5.3亿元不可退还的首付款与总计最高20.45亿元的里程碑款项。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440096.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","01477","BK4588","BK1191","02105","VXUS","BK1161","BK4585","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ocumension.com","stockEarnings":[{"period":"1week","weight":-0.0531},{"period":"1month","weight":-0.192},{"period":"3month","weight":-0.1607},{"period":"6month","weight":-0.2519},{"period":"1year","weight":-0.1192},{"period":"ytd","weight":-0.1811}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0146},{"period":"3month","weight":-0.0436},{"period":"6month","weight":-0.0134},{"period":"1year","weight":0.0995},{"period":"ytd","weight":-0.0012}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"欧康维视生物是一家主要从事眼科药物的研发和商业化的公司。该公司产品主要包括OT-401“优施莹”氟轻松玻璃体内植入剂、OT-702“博优景”阿柏西普眼内注射溶液、OT-402“维速达尔”注射用维替泊芬、OT-204“欧沁”玻璃酸钠滴眼液及OT-305“贝特舒”盐酸倍他洛尔滴眼液等。该公司产品主要用于治疗葡萄膜炎、眼底疾病、屈光矫正、干眼症（DED）、青光眼及角结膜炎等各种眼前及眼后段疾病。该公司主要在中国国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.097698},{"month":2,"riseRate":0.5,"avgChangeRate":-0.037557},{"month":3,"riseRate":0.5,"avgChangeRate":0.044668},{"month":4,"riseRate":0.5,"avgChangeRate":0.015642},{"month":5,"riseRate":0.5,"avgChangeRate":0.08405},{"month":6,"riseRate":0.8,"avgChangeRate":0.129408},{"month":7,"riseRate":0.4,"avgChangeRate":-0.027707},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.064893},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.082685},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.121217},{"month":11,"riseRate":0.333333,"avgChangeRate":0.004503},{"month":12,"riseRate":0.5,"avgChangeRate":0.058088}],"exchange":"SEHK","name":"欧康维视生物-B","nameEN":"OCUMENSION-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"欧康维视生物-B,01477,欧康维视生物-B股票,欧康维视生物-B股票老虎,欧康维视生物-B股票老虎国际,欧康维视生物-B行情,欧康维视生物-B股票行情,欧康维视生物-B股价,欧康维视生物-B股市,欧康维视生物-B股票价格,欧康维视生物-B股票交易,欧康维视生物-B股票购买,欧康维视生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}